11 assets in Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

Therapeutic assets addressing Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	OHSU Knight Cancer Institute	P2	B (60)
Ruxolitinib Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	St. Petersburg State Pavlov Medical University	P2	B (59)
Azacitidine Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	M.D. Anderson Cancer Center	P1/2	B (57)
Venetoclax Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	OHSU Knight Cancer Institute	P1/2	CCC (54)
Abatacept Recombinant Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	St. Petersburg State Pavlov Medical University	P2	CCC (53)
Nogitecan Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	National Cancer Institute (NCI)	P2	CCC (53)
Veliparib Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	National Cancer Institute (NCI)	P2	CCC (53)
Pevonedistat Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	M.D. Anderson Cancer Center	P1/2	CCC (48)